Seminars in Oncology
Volume 31, Issue 1 , Pages 22-26 , February 2004

Nonmyeloablative stem cell transplantation for lymphoma

  • Issa F Khouri

      Affiliations

    • Department of Blood and Marrow Transplantation, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
    • Corresponding Author InformationAddress reprint requests to Issa F. Khouri, MD, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA
    • ,
  • Richard E Champlin

      Affiliations

    • Department of Blood and Marrow Transplantation, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

References 

  1. Chopra R, Goldstone AH, Pearce R, et al.  Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma (A case-controlled analysis of the European Bone Marrow Transplant Group registry data). J Clin Oncol. 1992;10:1690–1695
  2. Van Besien K, Sobocinski A, Rowlings PA, et al.  Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92:1832–1836
  3. Demirer T, Weaver CH, Buckner CD, et al.  High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol. 1995;13:596–602
  4. Kolb HJ, Schattenberg A, Goldman JM, et al.  Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  5. Khouri IF, Keating MJ, Vriesendorp HM, et al.  Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia (Preliminary results). J Clin Oncol. 1994;12:748–758
  6. Verdonck LF, Dekker AW, Lokhorst HM, et al.  Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:4201–4205
  7. Van Besien KW, de Lima M, Giralt SA, et al.  Management of lymphoma recurrence after allogeneic transplantation (The relevance of graft-versus-lymphoma effect). Bone Marrow Transplant. 1997;19:977–982
  8. Champlin R, Khouri I, Kornblau S, et al.  Reinventing bone marrow transplantation (reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy). Curr Opin Oncol. 1999;11:87–95
  9. Khouri IF, Saliba RM, Giralt SA, et al.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma (Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality). Blood. 2001;98:3595–3599
  10. Khouri IF, Keating M, Körbling M, et al.  Transplant-lite (induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies). J Clin Oncol. 1998;16:2817–2824
  11. Gandhi V, Kemena A, Keating MJ, et al.  Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymph. 1993;10:49–56
  12. Czuczman MS, Grillo-Lopez AJ, White CA, et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276
  13. O’Brien SM, Kantarjian H, Thomas D, et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165–2170
  14. Velasquez WS, Cabanillas F, Salvador P, et al.  Effective salvage therapy for lymphoma in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1998;71:117–122
  15. Gandhi V, Kemena A, Keating MJ, et al.  Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992;52:897–903
  16. Li L, Keating MJ, Plunkett W, et al.  Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis k562 cells (Induction of synergistic cytotoxicity independent of reversal of apoptosis resistance). Mol Pharmacol. 1997;52:798–806
  17. Przepiorka D, Weisdorf D, Martin P, et al.  Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  19. Robinson SP, Mackinnon S, Goldstone AH, et al.  Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely effects progression free survival. Blood. 2000;96:554a; (abstr)

☆ Supported by grants from G & P Foundation for Cancer Research and Berlex Laboratories.

PII: S0093-7754(03)00560-8

doi: 10.1053/j.seminoncol.2003.10.017

Seminars in Oncology
Volume 31, Issue 1 , Pages 22-26 , February 2004

Article Tools

* Image Usage & Resolution